CJC-1295 Q3 2026: what actually changed

The third quarter of 2026 gave CJC-1295 its first proper evidence grading and, at the same time, confirmed that it has no scheduled route to lawful compounding in the United States. On 23 and 24 July the FDA's Pharmacy Compounding Advisory Committee voted on seven peptides and recommended six of them for the section 503A Bulks List. CJC-1295 was not one of the seven^[2]. A narrative review published in Frontiers in Endocrinology on 18 June went further than any previous paper and placed the two molecules sold under the CJC-1295 name into separate evidence tiers, B and D^[1].

The compounding vote happened without CJC-1295

The advisory committee met at the FDA's White Oak campus and worked through BPC-157, KPV, TB-500, MOTS-c, emideltide (also called delta sleep-inducing peptide), Semax and Epitalon. Six cleared. BPC-157, KPV and TB-500 each passed 8-6-1, MOTS-c passed 7-5-2, Epitalon 7-4-1 and Semax 8-5-1. Emideltide failed 6-7-1. FDA staff reviewers had recommended against all seven, so every affirmative vote went against the agency's own review^[2].

Two things follow for readers tracking CJC-1295. The first is that the votes are recommendations. They do not add anything to the 503A Bulks List, they do not authorise a pharmacy to compound anything, and formal rulemaking has to run its course before the legal position moves. The second is the more useful one: the peptides queued for the next advisory committee meeting, expected before the end of February 2027, are cathelicidin (LL-37), GHK-Cu, dihexa acetate, melanotan II and pegylated mechano growth factor^[3]. CJC-1295 is absent from that list too. It was not reviewed in July and it is not booked for February.

That is a change from where the coverage sat three months ago. Through the spring it was reasonable to describe CJC-1295 as waiting its turn behind the first tranche of peptides. Both dockets are now public and it is on neither. Nothing about that is a ruling on safety or efficacy. It simply means no US regulatory body is currently scheduled to make a finding either way.

The first review that grades CJC-1295 by tier

The genuinely new document this quarter is a narrative review by Dominikowski and colleagues at Poznan University of Medical Sciences, published in Frontiers in Endocrinology on 18 June 2026. It covers the peptides people buy to push on the growth hormone and IGF-1 axis, including CJC-1295 and ipamorelin, and it does something the earlier 2026 reviews did not: it sorts each compound into an explicit evidence tier and states what the tier rests on^[1].

CJC-1295 with DAC, the original ConjuChem molecule with the albumin-binding linker, lands in Tier B, defined as "phase I/II human studies (PK/PD, endocrine, or paediatric GHD-related), without controlled efficacy data for body-composition or performance endpoints". CJC-1295 without DAC, the short-acting peptide also called MOD-GRF(1-29), lands in Tier D: "no peer-reviewed human studies, with claims resting on preclinical extrapolation and grey-literature user narratives". The authors write that the without-DAC form "remains essentially uncharacterised in the peer-reviewed human literature" and that assertions about growth hormone pulsatility or body composition "derive largely from extrapolation" rather than from direct clinical evidence^[1].

The review also records what the online protocols actually say, which is where the gap gets uncomfortable. For the without-DAC form it documents self-administration of 100 to 200 micrograms per injection, once or twice daily, frequently combined with ipamorelin, against a Tier D evidence base. The authors are direct about the mismatch:

user-oriented platforms provide detailed 'stacking,' cycling, and dosing narratives that are often presented with a level of certainty not supported by the underlying data

What the tiering means for the version most people buy

Tier B sounds reassuring until you look at what fills it. The human dataset behind CJC-1295 with DAC is still Teichman and colleagues in 2006: two randomised, placebo-controlled ascending-dose trials in healthy adults aged 21 to 61, reporting a half-life of 5.8 to 8.1 days, mean plasma growth hormone raised 2 to 10 fold for six days or more, and IGF-1 raised 1.5 to 3 fold for 9 to 11 days after a single subcutaneous dose^[5]. That work is twenty years old, it measured pharmacokinetics rather than clinical outcomes, and nothing has replaced it.

The tier that matters more commercially is D, because the without-DAC peptide is what most vendors ship when a product page says CJC-1295. The two molecules are priced and marketed as one thing and behave as two, and the 2026 review is the first paper we have seen that separates them by evidence grade rather than only by structure. The full breakdown of both molecules sits on the CJC-1295 peptide page.

The same review is blunt about what arrives in the vial. It describes "variable composition, sterility, and purity in unregulated supply chains" and states that "sterility cannot be assumed in informal distribution channels"^[1]. None of the July compounding activity touches product identity or labelling standards for CJC-1295, so that problem is unchanged.

The doping literature caught up as well

A second paper reached its print issue this quarter. Coutinho, de Oliveira Neves and Camilo published a critical review in the Journal of Sports Medicine and Physical Fitness, July 2026 issue, on peptide and peptide-analogue use in recreational and professional sport. CJC-1295 is named among the growth hormone-releasing hormone analogues "promoted for muscle growth, fat metabolism, recovery, and anti-inflammatory effects", alongside sermorelin, ipamorelin and the fragments^[4]. The framing is the same as the endocrinology review: marketed as selective and safer, characterised by research gaps. The same S2 capture that applies to CJC-1295 applies to its licensed cousin tesamorelin and to ipamorelin on the secretagogue side. CJC-1295 remains prohibited in and out of competition under section S2 of the WADA list.

What did not change

No new human data. No trial registration. No completed phase 2 or phase 3 study in any indication. Three months of coverage produced two review papers and one advisory committee meeting that did not concern this molecule, and that absence is the honest headline of the quarter. The theoretical worry is also unchanged: the Frontiers review lists mitogenic growth hormone and IGF-1 signalling as a theoretical oncologic concern for CJC-1295 with DAC while noting there is no established clinical carcinogenic signal. Neither half of that sentence has moved since 2006.

Practical context

For anyone following the regulatory thread, the next fixed date is the advisory committee meeting expected before the end of February 2027, and CJC-1295 is not on it. For anyone weighing the evidence, the useful new artefact is the tier table in the Frontiers review, because it puts a name to what has been obvious for years: the molecule with human data is not the molecule being sold. The regulatory section of the peptide page tracks the country-by-country picture, and tesamorelin is the comparison worth reading, because it is the GHRH analogue in this family that went through a full approval process. If you are considering any growth hormone secretagogue, that decision belongs with a clinician who knows your history and can order the bloodwork to check what the compound is doing to your glucose and IGF-1.